HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Data Supplement Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Parkinson Study Group Search for Related Content PubMed PubMed Citation Articles by Parkinson Study Group,

The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD

Address correspondence and reprint requests to Dr. S.R. Schwid, Department of Neurology, University of Rochester Medical Center, 601 Elmwood Ave., Box 605, Rochester, NY 14642; e-mail: steven_schwid{at}urmc.rochester.edu

CEP-1347 is an inhibitor of members of the mixed lineage kinase family, key signals triggering apoptotic neuronal death. The authors performed a randomized, blinded, placebo-controlled study assessing the safety, tolerability, pharmacokinetics, and acute symptomatic effects of CEP-1347 in 30 patients with Parkinson’s disease (PD). In this short-term study, CEP-1347 was safe and well tolerated. It had no acute effect on parkinsonian symptoms or levodopa pharmacokinetics, making it well suited for larger and longer studies of its potential to modify the course of PD.

Received May 28, 2003. Accepted in final form October 10, 2003.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the January 27 issue to find the title link for this article.

*See the Appendix on page 332 for a list of contributing members.

This article has been cited by other articles:

				T. Thalhamer, M. A. McGrath, and M. M. Harnett MAPKs and their relevance to arthritis and inflammation Rheumatology, April 1, 2008; 47(4): 409 - 414. [Abstract] [Full Text] [PDF]

				R. Mishra, M. K. Barthwal, G. Sondarva, B. Rana, L. Wong, M. Chatterjee, J. R. Woodgett, and A. Rana Glycogen Synthase Kinase-3beta Induces Neuronal Cell Death via Direct Phosphorylation of Mixed Lineage Kinase 3 J. Biol. Chem., October 19, 2007; 282(42): 30393 - 30405. [Abstract] [Full Text] [PDF]

				The Parkinson Study Group PRECEPT Investigators Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease Neurology, October 9, 2007; 69(15): 1480 - 1490. [Abstract] [Full Text] [PDF]

				F. Y. Ma, R. S. Flanc, G. H. Tesch, Y. Han, R. C. Atkins, B. L. Bennett, G. C. Friedman, J.-H. Fan, and D. J. Nikolic-Paterson A Pathogenic Role for c-Jun Amino-Terminal Kinase Signaling in Renal Fibrosis and Tubular Cell Apoptosis J. Am. Soc. Nephrol., February 1, 2007; 18(2): 472 - 484. [Abstract] [Full Text] [PDF]

				A. B. West, D. J. Moore, C. Choi, S. A. Andrabi, X. Li, D. Dikeman, S. Biskup, Z. Zhang, K.-L. Lim, V. L. Dawson, et al. Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity Hum. Mol. Genet., January 15, 2007; 16(2): 223 - 232. [Abstract] [Full Text] [PDF]

				Z. Sui, S. Fan, L. Sniderhan, E. Reisinger, A. Litzburg, G. Schifitto, H. A. Gelbard, S. Dewhurst, and S. B. Maggirwar Inhibition of Mixed Lineage Kinase 3 Prevents HIV-1 Tat-Mediated Neurotoxicity and Monocyte Activation J. Immunol., July 1, 2006; 177(1): 702 - 711. [Abstract] [Full Text] [PDF]